Pluristem Therapeutics Inc.  

(Public, NASDAQ:PSTI)   Watch this stock  
Find more results for psti
+0.01 (0.42%)
Jul 29 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.38 - 2.44
52 week 2.27 - 3.78
Open 2.40
Vol / Avg. 256,055.00/188,788.00
Mkt cap 188.41M
P/E     -
Div/yield     -
EPS -0.37
Shares 78.50M
Beta 0.72
Inst. own 7%
Jun 4, 2015
Pluristem Therapeutics Inc at Jefferies Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -7606.32% -7106.07%
Operating margin -7925.26% -7348.28%
EBITD margin - -6987.34%
Return on average assets -51.40% -37.84%
Return on average equity -61.22% -45.04%
Employees 142 -
CDP Score - -


Building #5 #20, MATAM Advanced Technology Park
HAIFA, 31905
+972-74-7108600 (Phone)
+972-74-7108765 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Pluristem Therapeutics Inc (Pluristem) is a clinical-stage biotechnology company. Pluristem uses placental cells and a unique, proprietary, three-dimensional (3D) technology platform to develop cell therapies for a broad spectrum of diseases. Pluristem derives its cell products from human placental cells. Pluristem’s pipeline targets multiple indications involving inflammation and ischemia, including peripheral artery disease, muscle injury, preeclampsia, and graft versus host disease. PLX cells are a cell therapy product defined as mesenchymal-like adherent stromal cells (ASCs) derived from full term human placentas. Pluristem manufactures placenta-based cell products using a 3D bioreactor. Pluristem is pursuing multiple indications including Cardiovascular, Orthopedic, Pulmonary and Hematological diseases as well as preeclampsia. Through Pluristem’s in-house manufacturing facility the Company produces homogeneous, clinical-grade cells.

Officers and directors

Zami Aberman Chairman of the Board, Chief Executive Officer
Age: 60
Bio & Compensation  - Reuters
Yaky Yanay CPA President, Chief Operating Officer
Age: 43
Bio & Compensation  - Reuters
Boaz Gur-Lavie Chief Financial Officer, Secretary
Age: 41
Bio & Compensation  - Reuters
Doron Shorrer CPA Lead Independent Director
Age: 62
Bio & Compensation  - Reuters
Moria Kwiat Director
Age: 35
Bio & Compensation  - Reuters
Hava Meretzki Director
Age: 46
Bio & Compensation  - Reuters
Israel Ben-Yoram Independent Director
Age: 54
Bio & Compensation  - Reuters
Issac Braun Independent Director
Age: 62
Bio & Compensation  - Reuters